BioXytran is developing an innovative platform of oxygen treatments designed to address hypoxic conditions and help prevent tissue necrosis. Our initial areas of focus include:
Many of these conditions can benefit from hyperbaric oxygen therapy (HBOT), which has demonstrated clinical promise by increasing oxygen delivery to damaged tissues. However, HBOT has important limitations. Treatment is costly, requires specialized facilities, and the duration of therapy is restricted because prolonged exposure to high oxygen concentrations can lead to oxygen toxicity.
BioXytran's oxygen transport molecule has been designed to help overcome these limitations. While hyperbaric chamber treatments are typically limited to approximately one hour and may contribute to the formation of free radicals in the bloodstream, our approach is intended to deliver the appropriate form of oxygen while minimizing the generation of free radicals associated with oxygen toxicity.
Oxygen is indispensable to the survival and function of every human tissue.
Under normal physiological conditions, hemoglobin, a protein contained within red blood cells (RBCs), carries and releases oxygen throughout the body. Hemoglobin has a remarkably similar protein structure across many animal species, including humans.
Approximately 98% of the body's oxygen is transported by hemoglobin within red blood cells, while the remaining 2% is dissolved in blood plasma, the liquid component of blood.
When tissues do not receive an adequate oxygen supply, cellular damage can occur, contributing to numerous acute and chronic diseases. Improving oxygen delivery to oxygen-deprived tissues has the potential to improve outcomes across a range of medical conditions.
Many degenerative diseases are influenced by insufficient oxygen delivery to affected tissues. In these situations, restoring oxygenation as early as possible may improve clinical outcomes.
BioXytran's investigational solution, BXT-25, is an oxygen transport molecule designed to carry the same amount of oxygen as the hemoglobin molecules found in red blood cells (RBCs). By supporting oxygen delivery to hypoxic tissues, BXT-25 is being investigated as a potential therapeutic approach for conditions where oxygen deprivation contributes to disease progression.
BioXytran, Inc. is currently conducting active research into therapies for several diseases where oxygen delivery and tissue hypoxia may play an important role, including:
Select a condition above to learn more about the disease and how BioXytran's ongoing research may apply.
